| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. | Chief Commercial Officer | Common Stock | 5.69K | $79.7K | $14.00 | Dec 4, 2024 | Direct |
| ARS Pharmaceuticals, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 585K | Dec 4, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | Dec 2, 2024 | 6 | -$125K | 4 | Dec 4, 2024 | Chief Commercial Officer |
| SPRY | ARS Pharmaceuticals, Inc. | Sep 18, 2024 | 3 | -$125K | 4 | Sep 19, 2024 | Chief Commercial Officer |
| SPRY | ARS Pharmaceuticals, Inc. | Aug 19, 2024 | 3 | -$125K | 4 | Aug 21, 2024 | Chief Commercial Officer |
| SPRY | ARS Pharmaceuticals, Inc. | Jan 2, 2024 | 1 | $0 | 4 | Jan 4, 2024 | Chief Commercial Officer |
| SPRY | ARS Pharmaceuticals, Inc. | Jan 3, 2023 | 1 | $0 | 4 | Jan 5, 2023 | Chief Commercial Officer |
| SPRY | ARS Pharmaceuticals, Inc. | Nov 8, 2022 | 1 | $0 | 4 | Nov 10, 2022 | Chief Commercial Officer |
| SPRY | ARS Pharmaceuticals, Inc. | Nov 8, 2022 | 0 | $0 | 3 | Nov 10, 2022 | Chief Commercial Officer |